Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+lymphoid malignancies

Bibliographic Details
Title: Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+lymphoid malignancies
Authors: Frigault, Matthew J., Graham, Charlotte E., Berger, Trisha R., Ritchey, Julie, Horick, Nora K., El-Jawahri, Areej, Scarfò, Irene, Schmidts, Andrea, Haradhvala, Nicholas J., Wehrli, Marc, Lee, Won-Ho, Parker, Aiyana L., Wiggin, Hadley R., Bouffard, Amanda, Dey, Aonkon, Leick, Mark B., Katsis, Katelin, Elder, Eva L., Dolaher, Maria A., Cook, Daniella T., Chekmasova, Alena A., Huang, Lu, Nikiforow, Sarah, Daley, Heather, Ritz, Jerome, Armant, Myriam, Preffer, Fred, DiPersio, John F., Nardi, Valentina, Chen, Yi-Bin, Gallagher, Kathleen M. E., Maus, Marcela V.
Source: Blood; September 2024, Vol. 144 Issue: 11 p1153-1167, 15p
Abstract: •CAR-37 T cells expanded to >98% of T cells and led to complete responses but caused severe cytopenia associated with high levels of IL-18.•Depleting CAR-37 T cells using cetuximab to target the safety switch was unsuccessful in the setting of neutropenia.
Database: Supplemental Index
More Details
ISSN:00064971
15280020
DOI:10.1182/blood.2024024104
Published in:Blood
Language:English